Paper · 2026 · Open access

Review on Artificial Intelligence (AI) in Pharmaceutical Field

Suraj Zunzulde*, Tanuja Tandale, Dr. Sujit Kakade, Dr. Ashok Bhosale

Zenodo (CERN European Organization for Nuclear Research) · Published 22 February 2026 · DOI 10.5281/zenodo.18730245

Read the free full textCite this paper

In brief

“Review on Artificial Intelligence (AI) in Pharmaceutical Field” is a 2026 paper by Suraj Zunzulde*, Tanuja Tandale, Dr. Sujit Kakade, Dr. Ashok Bhosale, published in Zenodo (CERN European Organization for Nuclear Research). OpenAlex counts 2 citations as of 15 November 2026, which puts it in the top 5% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at Zenodo (CERN European Organization for Nuclear Research).

Citations
2
Most cited in
2026 (2)
Field-weighted impact
3.16
Authors
1

Abstract

Artificial Intelligence (AI) has become a powerful and transformative tool in pharmaceutical sciences, providing advanced approaches to overcome traditional challenges in drug discovery, development, formulation, and clinical decision- making. The pharmaceutical sector is under continuous pressure to shorten development timelines, reduce costs, and improve the success rate of new drug candidates while ensuring safety and therapeutic effectiveness. AI-based technologies such as machine learning (ML), deep learning (DL), natural language processing (NLP), and generative modeling have significantly improved the processes of target identification, molecular interaction prediction, and lead optimization. These computational techniques allow rapid screening of extensive chemical databases, accurate prediction of pharmacokinetic and toxicological (ADMET) profiles, simulation of virtual clinical trials, and implementation of personalized treatment strategies using real-world data. Furthermore, AI contributes to pharmaceutical formulation development by predicting drug–excipient compatibility, optimizing manufacturing parameters, and maintaining product quality through advanced Quality by Design (QbD) frameworks. In pharmacovigilance, AI enhances the monitoring of drug safety by enabling automated adverse event detection, signal generation, and risk evaluation through analysis of electronic health records, clinical databases, and social media sources. Although AI offers significant advantages, its widespread adoption faces challenges including data security issues, lack of algorithm transparency, regulatory uncertainties, and the requirement for robust, high-quality datasets. This review outlines the present applications, recent technological developments, benefits, and limitations of AI in pharmaceutical research, emphasizing its expanding role in driving innovation and improving global healthcare outcomes.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Bhosale, S. Z. T. T. D. S. K. D. A. (2026). Review on Artificial Intelligence (AI) in Pharmaceutical Field. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.18730245

MLA 9

Bhosale, Suraj Zunzulde*, Tanuja Tandale, Dr. Sujit Kakade, Dr. Ashok. “Review on Artificial Intelligence (AI) in Pharmaceutical Field.” Zenodo (CERN European Organization for Nuclear Research), 2026. https://doi.org/10.5281/zenodo.18730245.

Chicago

Bhosale, Suraj Zunzulde*, Tanuja Tandale, Dr. Sujit Kakade, Dr. Ashok. 2026. “Review on Artificial Intelligence (AI) in Pharmaceutical Field.” Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.18730245.

Harvard

Bhosale, S. Z. T. T. D. S. K. D. A. (2026) ‘Review on Artificial Intelligence (AI) in Pharmaceutical Field’, Zenodo (CERN European Organization for Nuclear Research). doi:10.5281/zenodo.18730245.

IEEE

S. Z. T. T. D. S. K. D. A. Bhosale, “Review on Artificial Intelligence (AI) in Pharmaceutical Field,” Zenodo (CERN European Organization for Nuclear Research), 2026, doi: 10.5281/zenodo.18730245.

BibTeX

@article{bhosale2026review,
  title     = {{Review on Artificial Intelligence (AI) in Pharmaceutical Field}},
  author    = {Bhosale, Suraj Zunzulde*, Tanuja Tandale, Dr. Sujit Kakade, Dr. Ashok},
  journal   = {Zenodo (CERN European Organization for Nuclear Research)},
  year      = {2026},
  doi       = {10.5281/zenodo.18730245},
  url       = {https://doi.org/10.5281/zenodo.18730245}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • artificial intelligence in pharmaceuticals
  • drug discovery
  • drug development
  • machine learning
  • deep learning
  • natural language processing
  • generative models
  • target identification

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Bhosale, S. Z. T. T. D. S. K. D. A. (2026). Review on Artificial Intelligence (AI) in Pharmaceutical Field. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5281/zenodo.18730245

How many times has this paper been cited?

2 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Zenodo (CERN European Organization for Nuclear Research).

Who wrote this paper?

Suraj Zunzulde*, Tanuja Tandale, Dr. Sujit Kakade, Dr. Ashok Bhosale.

What is the DOI of this paper?

10.5281/zenodo.18730245. The permanent link is https://doi.org/10.5281/zenodo.18730245.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.